Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05652686 · ClinicalTrials.gov registry record · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
A Phase 1 study of Small Cell Lung Cancer (SCLC) and Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), sponsored by Phanes Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 203
- Enrollment target
- 12
- Study locations
NCT05652686 is a Phase 1 study of Small Cell Lung Cancer (SCLC) and Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) that is actively recruiting participants, run by Phanes Therapeutics. The registered enrollment target is 203 participants, below the 342-participant average among 9 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (41% lower). The trial reports 12 study locations across 10 states.
The verdict
NCT05652686, a Phase 1 study of Small Cell Lung Cancer (SCLC) and Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), is actively recruiting participants, sponsored by Phanes Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 203 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Peluntamig (PT217)
- DRUG Carboplatin + Etoposide
- DRUG Paclitaxel.
Study Locations (12)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Texas
- The University of Texas, MD Anderson Cancer Center - Houston
- Mays Cancer Center / University of Texas, San Antonio - San Antonio
California
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) - Duarte
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Maryland
- Sidney Kimmel Comprehensive Cancer Center at John Hopkins - Baltimore
Missouri
- Washington University School of Medicine (Siteman Cancer Center) - St Louis
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Oklahoma
- Sarah Cannon Research Institute University of Oklahoma - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2023-09-05 |
| Est. Completion | 2028-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05652686
The ClinicalTrials.gov registry entry for NCT05652686 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 342-participant average among 9 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (41% lower). The listed sponsor is Phanes Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Small Cell Lung Cancer (SCLC) appearing as the primary indexed condition, and to 4 interventions - of which Atezolizumab is the first listed.
NCT05652686 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Massachusetts, Texas, California.
Frequently Asked Questions
What is clinical trial NCT05652686 about?
NCT05652686 is a clinical study titled "A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)". This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
What is the current status of trial NCT05652686?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 203 participants. The study started on 2023-09-05. Estimated completion is 2028-08.
What conditions does trial NCT05652686 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer (SCLC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC).
What interventions are being tested in trial NCT05652686?
The interventions under investigation include: Atezolizumab (DRUG), Peluntamig (PT217) (DRUG), Carboplatin + Etoposide (DRUG), Paclitaxel. (DRUG).
Who is sponsoring clinical trial NCT05652686?
This trial is sponsored by Phanes Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05652686 being conducted?
This trial has 12 study locations across California, Colorado, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Cancer (SCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
RECRUITING · Phase 1
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
RECRUITING · Phase 1
-
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Small Cell Lung Cancer (SCLC)
All registered trials for this condition
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.